A New Peptide Drug Is Approved

It is nice to see new FDA-approved peptide-based drugs.  Recently, Synergy Pharmaceuticals received FDA approval for their uroguanylin derivative, TRULANCE™ (plecanatide), in adult patients.  Plecanatide is designed to mimic the function of uroguanylin.  Uroguanylin helps alleviate chronic idiopathic constipation (CIC) by increasing water levels in the gastrointestinal tract.  The drug is also being evaluated for treatment of chronic irritable bowel syndrome.1 Unlike many other peptide drugs, plecanatide is an oral medication.  The market is underserved and rather large with approximately 42 million people having CIC, according to the National Institutes of Health.2


1.    http://ir.synergypharma.com/press-releases/detail/1831/synergy-pharmaceuticals-trulance-plecanatide and http://www.synergypharma.com/research-and-development/uroguanylin
2.   http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm537725.htm

Industry News , Biologically Active Peptides

Dr. Michael W. Pennington

See all articles from Dr. Michael W. Pennington

Dr. Michael Pennington joined Peptides International in December 2010 as Chief Technology Officer. On January 1, 2013, Dr. Pennington's role became that of President and Chief Executive Officer. After doctoral research at University of Florida, he joined the pharmaceutical industry in the Department of Biotechnology at Schering-Plough. He joined Bachem Biosciences in King of Prussia, PA as a Principle Scientist in the Peptide Chemistry department. Dr. Pennington served as the Group Director for Bachem Biosciences before being appointed as President and C.O.O., a positioned he maintained from 2000 – 2010. He built and directed an internationally recognized peptide chemistry team focused on producing complex peptides and toxins. Dr. Pennington was a member of Bachem Forschungausschuss, the International Research and Development from 2000 – 2010. He has extensive collaborations with both industrial and academic scientists and maintains an extramurally funded research program on several peptide toxins. He is a founder of Airmid Inc., a biotech venture company dedicated to advancing two of his discoveries into clinical development for autoimmune diseases. Dr. Pennington has been awarded four patents and over 85 peer reviewed scientific articles, and serves as an editor of International Journal of Peptide Research and Therapeutics and Current Peptide and Protein Letters. He holds a Bachelor of Chemistry degree from the University of North Carolina at Chapel Hill and a Ph.D. from University of Florida at Gainesville.